Targets for adjunctive therapy in pneumococcal meningitis

Journal of Neuroimmunology

Volumn 278, Issue , 2015, Pages 262-270

  Barichello, Tatiana ^a,b   Collodel, Allan ^b   Generoso, Jaqueline S ^b   Simões, Lutiana R ^b   Moreira, Ana Paula ^b   Ceretta, Renan A ^b   Petronilho, Fabrícia ^a,c   Quevedo, João ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Meningitis; Streptococcus pneumoniae; Targets of adjunctive therapy

Indexed keywords

ACETYLCYSTEINE; AG 126; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; CASPASE 3 INHIBITOR; CORTICOSTEROID DERIVATIVE; DAPTOMYCIN; DEFEROXAMINE; ERYTHROPOIETIN; FUCOIDIN; GELATINASE A; GELATINASE B; GLYCEROL; MATRIX METALLOPROTEINASE INHIBITOR; PATTERN RECOGNITION RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; SCAVENGER; TOLL LIKE RECEPTOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN B COMPLEX; ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; BLOOD BRAIN BARRIER; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; INDUCED HYPOTHERMIA; INFECTION CONTROL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PNEUMOCOCCAL MENINGITIS; REVIEW; STREPTOCOCCUS PNEUMONIAE; BRAIN; COMPLICATION; DRUG EFFECTS; MENINGITIS, PNEUMOCOCCAL; METABOLISM; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; BRAIN; HUMANS; MENINGITIS, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84920933150     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.11.015     Document Type: Review

References (120)

1. Adhikari A., Xu M., Chen Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007, 26(22):3214-3226.
2. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002, 952(1):128-134.
3. Ajdukiewicz K.M., Cartwright K.E., Scarborough M., Mwambene J.B., Goodson P., Molyneux M.E., et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect. Dis. 2011, 11(4):293-300.
4. Alvarez F.J., Lafuente H., Rey-Santano M.C., Mielgo V.E., Gastiasoro E., Rueda M., et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr. Res. 2008, 64(6):653-658.
5. Angstwurm K., Weber J.R., Segert A., Burger W., Weih M., Freyer D., et al. Fucoidin, a polysaccharide inhibiting leukocyte rolling, attenuates inflammatory responses in experimental pneumococcal meningitis in rats. Neurosci. Lett. 1995, 191(1-2):1-4.
6. Angstwurm K., Reuss S., Freyer D., Arnold G., Dirnagl U., Schumann R.R., et al. Induced hypothermia in experimental pneumococcal meningitis. J. Cereb. Blood Flow Metab. 2000, 20(5):834-838.
7. Angstwurm K., Hanisch U.K., Gassemi T., Bille M.B., Prinz M., Dirnagl U., et al. Tyrosine kinase inhibition reduces inflammation in the acute stage of experimental pneumococcal meningitis. Infect. Immun. 2004, 72(6):3294-3298.
8. Auer M., Pfister L.A., Leppert D., Tauber M.G., Leib S.L. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J. Infect. Dis. 2000, 182(1):347-350.
9. Barichello T., Machado R.A., Constantino L., Valvassori S.S., Reus G.Z., Martins M.R., et al. Antioxidant treatment prevented late memory impairment in an animal model of sepsis. Crit. Care Med. 2007, 35(9):2186-2190.
10. Barichello T., Santos A.L., Silvestre C., Generoso J.S., Cipriano A.L., Petronilho F., et al. Dexamethasone treatment reverses cognitive impairment but increases brain oxidative stress in rats submitted to pneumococcal meningitis. Oxidative Med. Cell. Longev. 2011, 173035(10):21.
11. Barichello T., Generoso J.S., Collodel A., Moreira A.P., Almeida S.M. Pathophysiology of acute meningitis caused by Streptococcus pneumoniae and adjunctive therapy approaches. Arq. Neuropsiquiatr. 2012, 70(5):366-372.
12. Barichello T., Santos A.L., Savi G.D., Generoso J.S., Otaran P., Michelon C.M., et al. Antioxidant treatment prevents cognitive impairment and oxidative damage in pneumococcal meningitis survivor rats. Metab. Brain Dis. 2012, 27(4):587-593.
13. Barichello T., Ceretta R.A., Generoso J.S., Moreira A.P., Simoes L.R., Comim C.M., et al. Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur. J. Pharmacol. 2012, 697(1-3):158-164.
14. Barichello T., Generoso J.S., Simoes L.R., Elias S.G., Quevedo J. Role of oxidative stress in the pathophysiology of pneumococcal meningitis. Oxidative Med. Cell. Longev. 2013, 2013:371465.
15. Barichello T., Generoso J.S., Milioli G., Elias S.G., Teixeira A.L. Pathophysiology of bacterial infection of the central nervous system and its putative role in the pathogenesis of behavioral changes. Rev. Bras. Psiquiatr. 2013, 35(1):81-87.
16. Barichello T., Simoes L.R., Generoso J.S., Sangiogo G., Danielski L.G., Florentino D., et al. Erythropoietin prevents cognitive impairment and oxidative parameters in Wistar rats subjected to pneumococcal meningitis. Transl. Res. 2013, 25(13):462-463.
17. Barichello T., Lemos J.C., Generoso J.S., Carradore M.M., Moreira A.P., Collodel A., et al. Evaluation of the brain-derived neurotrophic factor, nerve growth factor and memory in adult rats survivors of the neonatal meningitis by Streptococcus agalactiae. Brain Res. Bull. 2013, 92:56-59.
18. Barichello T., Goncalves J.C., Generoso J.S., Milioli G.L., Silvestre C., Costa C.S., et al. Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis. BMC Neurosci. 2013, 14(42):1471-2202.
19. Barichello T., Generoso J.S., Simoes L.R., Elias S.G., Tashiro M.H., Dominguini D., et al. Inhibition of indoleamine 2,3-dioxygenase prevented cognitive impairment in adult Wistar rats subjected to pneumococcal meningitis. Transl. Res. 2013, 162(6):390-397.
20. Barichello T., Generoso J.S., Michelon C.M., Simoes L.R., Elias S.G., Vuolo F., et al. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp. Biol. Med. 2014, 239(2):225-231.
21. Barichello T., Generoso J.S., Simoes L.R., Ceretta R.A., Dominguini D., Ferrari P., et al. Vitamin B6 prevents cognitive impairment in experimental pneumococcal meningitis. Exp. Biol. Med. (Maywood, NJ) 2014, 239(10):1360-1365.
22. Bellac C.L., Coimbra R.S., Christen S., Leib S.L. Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. Neurobiol. Dis. 2006, 24(2):395-402.
23. Bifrare Y.D., Kummer J., Joss P., Tauber M.G., Leib S.L. Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis. J. Infect. Dis. 2005, 191(1):40-45.
24. Blaser C., Klein M., Grandgirard D., Wittwer M., Peltola H., Weigand M., et al. Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis. BMC Infect. Dis. 2010, 10:84.
25. Blaser C., Wittwer M., Grandgirard D., Leib S.L. Adjunctive dexamethasone affects the expression of genes related to inflammation, neurogenesis and apoptosis in infant rat pneumococcal meningitis. PLoS One 2011, 6(3):0017840.
26. Brandt C.T., Lundgren J.D., Frimodt-Moller N., Christensen T., Benfield T., Espersen F., et al. Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. J. Neuroimmunol. 2005, 166(1-2):126-131.
27. Braun J. Inducible nitric oxide synthase mediates hippocampal caspase-3 activation in pneumococcal meningitis. Int. J. Neurosci. 2009, 119(4):455-459.
28. Braun J.S., Novak R., Murray P.J., Eischen C.M., Susin S.A., Kroemer G., et al. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J. Infect. Dis. 2001, 184(10):1300-1309.
29. Brouwer M.C., McIntyre P., Prasad K., van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 2013, 4(6).
30. Calapai G., Marciano M.C., Corica F., Allegra A., Parisi A., Frisina N., et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 2000, 401(3):349-356.
31. Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M., Alvarez D., Al-Dalain S., Martinez G., et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem. 2003, 86(3):545-555.
32. Candelario-Jalil E., Taheri S., Yang Y., Sood R., Grossetete M., Estrada E.Y., et al. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J. Pharmacol. Exp. Ther. 2007, 323(2):488-498.
33. Carlos T.M., Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 1994, 84(7):2068-2101.
34. Cassol-Jr O.J., Comim C.M., Silva B.R., Hermani F.V., Constantino L.S., Felisberto F., et al. Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res. 2010, 12:128-138.
35. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(20):11715-11720.
36. Chattopadhyay A., Choudhury T.D., Bandyopadhyay D., Datta A.G. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem. Pharmacol. 2000, 59(4):419-425.
37. Chau M., Chen D., Wei L. Erythropoietin attenuates inflammatory factors and cell death in neonatal rats with intracerebral hemorrhage. Acta Neurochir. Suppl. 2011, 111:299-305.
38. Chin K., Yu X., Beleslin-Cokic B., Liu C., Shen K., Mohrenweiser H.W., et al. Production and processing of erythropoietin receptor transcripts in brain. Brain Res. Mol. Brain Res. 2000, 81(1-2):29-42.
39. Christen S., Bifrare Y.D., Siegenthaler C., Leib S.L., Tauber M.G. Marked elevation in cortical urate and xanthine oxidoreductase activity in experimental bacterial meningitis. Brain Res. 2001, 900(2):244-251.
40. Christen S., Schaper M., Lykkesfeldt J., Siegenthaler C., Bifrare Y.D., Banic S., et al. Oxidative stress in brain during experimental bacterial meningitis: differential effects of alpha-phenyl-tert-butyl nitrone and N-acetylcysteine treatment. Free Radic. Biol. Med. 2001, 31(6):754-762.
41. Coimbra R.S., Loquet G., Leib S.L. Limited efficacy of adjuvant therapy with dexamethasone in preventing hearing loss due to experimental pneumococcal meningitis in the infant rat. Pediatr. Res. 2007, 62(3):291-294.
42. Comim C.M., Cassol O.J., Abreu I., Moraz T., Constantino L.S., Vuolo F., et al. Erythropoietin reverts cognitive impairment and alters the oxidative parameters and energetic metabolism in sepsis animal model. J. Neural Transm. 2012, 119(11):1267-1274.
43. Cottagnoud P., Pfister M., Acosta F., Cottagnoud M., Flatz L., Kuhn F., et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 2004, 48(10):3928-3933.
44. Dhobale M., Joshi S. Altered maternal micronutrients (folic acid, vitamin B(12)) and omega 3 fatty acids through oxidative stress may reduce neurotrophic factors in preterm pregnancy. J. Matern. Fetal Neonatal Med. 2012, 25(4):317-323.
45. Donega V., van Velthoven C.T., Nijboer C.H., van Bel F., Kas M.J., Kavelaars A., et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One 2013, 8(1):e51253.
46. Donnelly S., Loscher C., Mills K.H., Lynch M.A. Glycerol-induced seizure: involvement of IL-1beta and glutamate. Neuroreport 1999, 10(9):1821-1825.
47. Edmond K., Clark A., Korczak V.S., Sanderson C., Griffiths U.K., Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 2010, 10(5):317-328.
48. Egermann U., Stanga Z., Ramin A., Acosta F., Stucki A., Gerber P., et al. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob. Agents Chemother. 2009, 53(7):3030-3033.
49. Friso S., Jacques P.F., Wilson P.W., Rosenberg I.H., Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001, 103(23):2788-2791.
50. Genc S., Koroglu T.F., Genc K. Erythropoietin and the nervous system. Brain Res. 2004, 12:1-2.
51. Gerber J., Bottcher T., Hahn M., Siemer A., Bunkowski S., Nau R. Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. Neurobiol. Dis. 2004, 16(1):133-138.
52. Gianinazzi C., Grandgirard D., Imboden H., Egger L., Meli D.N., Bifrare Y.D., et al. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol. 2003, 105(5):499-507.
53. Gonzalez M.V., Gonzalez-Sancho J.M., Caelles C., Munoz A., Jimenez B. Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Lett. 1999, 459(2):272-276.
54. Grandgirard D., Schurch C., Cottagnoud P., Leib S.L. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 2007, 51(6):2173-2178.
55. Grandgirard D., Burri M., Agyeman P., Leib S.L. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob. Agents Chemother. 2012, 56(8):4289-4295.
56. Granert C., Raud J., Waage A., Lindquist L. Effects of polysaccharide fucoidan on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit. Infect. Immun. 1999, 67(5):2071-2074.
57. Hanisch U.K., Prinz M., Angstwurm K., Hausler K.G., Kann O., Kettenmann H., et al. The protein tyrosine kinase inhibitor AG126 prevents the massive microglial cytokine induction by pneumococcal cell walls. Eur. J. Immunol. 2001, 31(7):2104-2115.
58. Hanna S., Etzioni A. Leukocyte adhesion deficiencies. Ann. N. Y. Acad. Sci. 2012, 1250:50-55.
59. Hirst R.A., Kadioglu A., O'Callaghan C., Andrew P.W. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin. Exp. Immunol. 2004, 138(2):195-201.
60. Hofer S., Grandgirard D., Burri D., Frohlich T.K., Leib S.L. Bacterial meningitis impairs hippocampal neurogenesis. J. Neuropathol. Exp. Neurol. 2011, 70(10):890-899.
61. Hsieh H.L., Wang H.H., Wu C.Y., Tung W.H., Yang C.M. Lipoteichoic acid induces matrix metalloproteinase-9 expression via transactivation of PDGF receptors and NF-kappaB activation in rat brain astrocytes. Neurotox. Res. 2010, 17(4):344-359.
62. Hu X., Liou A.K., Leak R.K., Xu M., An C., Suenaga J., et al. Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles. Prog. Neurobiol. 2014, 119-120:60-84.
63. Huang S.C., Wei J.C., Wu D.J., Huang Y.C. Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. Eur. J. Clin. Nutr. 2010, 64(9):1007-1013.
64. Irazuzta J.E., Pretzlaff R., Rowin M., Milam K., Zemlan F.P., Zingarelli B. Hypothermia as an adjunctive treatment for severe bacterial meningitis. Brain Res. 2000, 881(1):88-97.
65. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009, 30(10):515-527.
66. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 1992, 72(2):449-489.
67. Kalani A., Kamat P.K., Givvimani S., Brown K., Metreveli N., Tyagi S.C., et al. Nutri-epigenetics ameliorates blood-brain barrier damage and neurodegeneration in hyperhomocysteinemia: role of folic acid. J. Mol. Neurosci. 2013, 13:13.
68. Kelesidis T. The interplay between daptomycin and the immune system. Front. Immunol. 2014, 5:52. (Feb 12. eCollection 2014).
69. Kenneth N.S., Mudie S., Naron S., Rocha S. TfR1 interacts with the IKK complex and is involved in IKK-NF-kappaB signalling. Biochem. J. 2013, 449(1):275-284.
70. Klein M., Koedel U., Pfister H.W. Oxidative stress in pneumococcal meningitis: a future target for adjunctive therapy?. Prog. Neurobiol. 2006, 80(6):269-280.
71. Koedel U., Pfister H.W. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci. Lett. 1997, 225(1):33-36.
72. Kronenberg G., Colla M., Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr. Mol. Med. 2009, 9(3):315-323.
73. Kumral A., Tuzun F., Oner M.G., Genc S., Duman N., Ozkan H. Erythropoietin in neonatal brain protection: the past, the present and the future. Brain Dev. 2011, 33(8):632-643.
74. Kutlesa M., Lepur D., Barsic B. Therapeutic hypothermia for adult community-acquired bacterial meningitis-historical control study. Clin. Neurol. Neurosurg. 2014, 123:181-186.
75. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(5259):680-685.
76. Leib S.L., Kim Y.S., Chow L.L., Sheldon R.A., Tauber M.G. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J. Clin. Invest. 1996, 98(11):2632-2639.
77. Leib S.L., Heimgartner C., Bifrare Y.D., Loeffler J.M., Taauber M.G. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr. Res. 2003, 54(3):353-357.
78. Leppert D., Leib S.L., Grygar C., Miller K.M., Schaad U.B., Hollander G.A. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin. Infect. Dis. 2000, 31(1):80-84.
79. Leppert D., Lindberg R.L., Kappos L., Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 2001, 36(2-3):249-257.
80. Li L., Shui Q.X., Liang K., Ren H. Brain-derived neurotrophic factor rescues neurons from bacterial meningitis. Pediatr. Neurol. 2007, 36(5):324-329.
81. Lukes A., Mun-Bryce S., Lukes M., Rosenberg G.A. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol. Neurobiol. 1999, 19(3):267-284.
82. Matte C., Pereira L.O., Dos Santos T.M., Mackedanz V., Cunha A.A., Netto C.A., et al. Acute homocysteine administration impairs memory consolidation on inhibitory avoidance task and decreases hippocampal brain-derived neurotrophic factor immunocontent: prevention by folic acid treatment. Neuroscience 2009, 163(4):1039-1045. (Epub Jul 18). 10.16/j.neuroscience.2009.07.023.
83. Meli D.N., Loeffler J.M., Baumann P., Neumann U., Buhl T., Leppert D., et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex. J. Neuroimmunol. 2004, 151(1-2):6-11.
84. Mitchell L., Smith S.H., Braun J.S., Herzog K.H., Weber J.R., Tuomanen E.I. Dual phases of apoptosis in pneumococcal meningitis. J. Infect. Dis. 2004, 190(11):2039-2046.
85. Mogensen T.H., Berg R.S., Paludan S.R., Ostergaard L. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae. Infect. Immun. 2008, 76(1):189-197.
86. Molyneux E.M., Kawaza K., Phiri A., Chimalizeni Y., Mankhambo L., Schwalbe E., et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatr. Infect. Dis. J. 2014, 33(2):214-216.
87. Mook-Kanamori B.B., Geldhoff M., van der Poll T., van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin. Microbiol. Rev. 2011, 24(3):557-591.
88. Mourvillier B., Tubach F., van de Beek D., Garot D., Pichon N., Georges H., et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA 2013, 310(20):2174-2183.
89. Nairz M., Sonnweber T., Schroll A., Theurl I., Weiss G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. / Inst. Pasteur 2012, 14(3):238-246.
90. Ortolani O., Conti A., De Gaudio A.R., Moraldi E., Cantini Q., Novelli G. The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock. Am. J. Respir. Crit. Care Med. 2000, 161(6):1907-1911.
91. Paterson R.L., Galley H.F., Webster N.R. The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit. Care Med. 2003, 31(11):2574-2578.
92. Paul R., Lorenzl S., Koedel U., Sporer B., Vogel U., Frosch M., et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 1998, 44(4):592-600.
93. Paul R., Koedel U., Winkler F., Kieseier B.C., Fontana A., Kopf M., et al. Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain 2003, 126(Pt 8):1873-1882.
94. Pazos M.R., Mohammed N., Lafuente H., Santos M., Martinez-Pinilla E., Moreno E., et al. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 2013, 71:282-291.
95. Peltola H., Roine I., Fernandez J., Zavala I., Ayala S.G., Mata A.G., et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 2007, 45(10):1277-1286.
96. Pfausler B., Schmutzhard E. Controversies in neurology, Vienna, 2012: steroids in bacterial meningitis: no. J. Neural Transm. 2013, 120(2):343-346.
97. Pfister H.W., Koedel U., Lorenzl S., Tomasz A. Antioxidants attenuate microvascular changes in the early phase of experimental pneumococcal meningitis in rats. Stroke 1992, 23(12):1798-1804.
98. Pirracchio R., Journois D. Hypothermia for bacterial meningitis. JAMA 2014, 311(13):1357.
99. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science (New York, NY) 1999, 284(5411):143-147.
100. Ploder M., Kurz K., Spittler A., Neurauter G., Roth E., Fuchs D. Early increase of plasma homocysteine in sepsis patients with poor outcome. Mol. Med. 2010, 16(11-12):498-504.
101. Ribeiro A., Ferraz-de-Paula V., Pinheiro M.L., Vitoretti L.B., Mariano-Souza D.P., Quinteiro-Filho W.M., et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur. J. Pharmacol. 2012, 678(1-3):78-85.
102. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 1992, 576(2):203-207.
103. Rosenberg G.A., Estrada E.Y., Dencoff J.E., Stetler-Stevenson W.G. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res. 1995, 703(1-2):151-155.
104. Ruiz-Valdepenas L., Martinez-Orgado J.A., Benito C., Millan A., Tolon R.M., Romero J. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J. Neuroinflammation 2011, 8(1):1742-2094.
105. Schmidt H., Stuertz K., Chen V., Stringaris A.K., Bruck W., Nau R. Glycerol does not reduce neuronal damage in experimental Streptococcus pneumoniae meningitis in rabbits. Inflammopharmacology 1998, 6(1):19-26.
106. Sellebjerg F., Sorensen T.L. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 2003, 61(3):347-355.
107. Shin S.H., Kim K.S. Treatment of bacterial meningitis: an update. Expert. Opin. Pharmacother. 2012, 13(15):2189-2206.
108. Singhi S., Jarvinen A., Peltola H. Increase in serum osmolality is possible mechanism for the beneficial effects of glycerol in childhood bacterial meningitis. Pediatr. Infect. Dis. J. 2008, 27(10):892-896.
109. Stucki A., Cottagnoud M., Winkelmann V., Schaffner T., Cottagnoud P. Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob. Agents Chemother. 2007, 51(6):2249-2252.
110. Tato C.M., Hunter C.A. Host-pathogen interactions: subversion and utilization of the NF-kappa B pathway during infection. Infect. Immun. 2002, 70(7):3311-3317.
111. Ulvik A., Theofylaktopoulou D., Midttun O., Nygard O., Eussen S.J., Ueland P.M. Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status. Am. J. Clin. Nutr. 2013, 98(4):934-940.
112. van de Beek D., de Gans J., Spanjaard L., Weisfelt M., Reitsma J.B., Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N. Engl. J. Med. 2004, 351(18):1849-1859.
113. van de Kamp J.L., Smolen A. Response of kynurenine pathway enzymes to pregnancy and dietary level of vitamin B-6. Pharmacol. Biochem. Behav. 1995, 51(4):753-758.
114. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav. Immun. 2010, 24(3):387-393.
115. van Velthoven C.T., Braccioli L., Willemen H.L., Kavelaars A., Heijnen C.J. Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage. Mol. Ther. 2014, 22(3):645-654.
116. Vital A.L., Goncalo M., Cruz M.T., Figueiredo A., Duarte C.B., Lopes M.C. Dexamethasone prevents granulocyte-macrophage colony-stimulating factor-induced nuclear factor-kappaB activation, inducible nitric oxide synthase expression and nitric oxide production in a skin dendritic cell line. Mediat. Inflamm. 2003, 12(2):71-78.
117. Woessner J.F. The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 1994, 732:11-21.
118. Zhang Z.X., Guan L.X., Zhang K., Zhang Q., Dai L.J. A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 2008, 10(2):134-139.
119. Zuardi A.W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008, 30(3):271-280.
120. Zysset-Burri D.C., Bellac C.L., Leib S.L., Wittwer M. Vitamin B6 reduces hippocampal apoptosis in experimental pneumococcal meningitis. BMC Infect. Dis. 2013, 13(393):1471-2334.